We pioneer unique products and therapies that harness and harmonize the body's natural systems.

Learn More About Us
Click here for more information about our
Heart Failure pivotal study, BeAT-HF


CVRx® developed a proprietary implantable technology for the treatment of heart failure and high blood pressure. BAROSTIM NEO™ uses CVRx-patented technology that is designed to trigger the body’s own natural blood flow regulation system to treat these conditions. BAROSTIM NEO™ can be adjusted to meet each patient’s individual therapy needs.

Learn More

Follow CVRx in the News

- See the 6 month data from the BeAT Heart Failure Study presented 9 May 2019 at HRS and 27 May 2019 at ESC-HF.
- CVRx® Announces First Two Patients Treated in Pivotal Trial Evaluating BAROSTIM THERAPY™ for the Treatment of Heart Failure
- CVRx® Announces Expedited Access Pathway Designation by FDA for BAROSTIM THERAPY™
- Heart Failure Clinical Trial Results Presented at ESC-Heart Failure 2015 Annual Conference

See All News

EUROPE:  The BAROSTIM NEO™ System is CE Marked and approved for sale for hypertension patients in the European Union (EU). It is also CE Marked and approved for sale for heart failure patients in the EU.

CAUTION:  Investigational device. Limited by Federal (or United States) law to investigational use.
CAUTION:  Federal law restricts this device to sale by or on the order of a physician. Humanitarian Device. Authorized by Federal law for use in the treatment of resistant hypertensive patients implanted with the Rheos CSL leads.  The effectiveness of this device has not been demonstrated.

CANADA ONLY:  CAUTION: Exclusively for Clinical Investigations

For a list of all potential benefits and risks go to www.cvrx.com/benefit-risk-analysis/